Premium
Intrexon Corporation (XON)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusiv... Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. Show more
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares PR Newswire GERMANTOWN, Md., Jan. 26, 2021 GERMANTOWN, Md., Jan. 26, 2021...
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference - Management will also participate in a panel discussion at the H.C. Wainwright BioConnect 2021 Conference - PR...
Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results - Company to provide comprehensive clinical pipeline and data updates in early December - - Continues to advance healthcare...
Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December PR Newswire GERMANTOWN, Md., Nov. 2, 2020 GERMANTOWN, Md...
Precigen Completes Series Of Transactions To Solidify Healthcare Focus - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon...
Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference - Company to Discuss First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure - PR...
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML) - Patients with AML have limited treatment options for this debilitating and...
Darling Ingredients Acquires 100% of EnviroFlight Expanding Investment in Innovative Specialty Proteins and Feed Sustainability PR Newswire IRVING, Texas, Jan. 2, 2020 IRVING, Texas, Jan. 2, 2020...
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus --Concurrent asset and stock sales reduce...
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting PR...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
